Table 6.
RA |
IH |
|||||||
---|---|---|---|---|---|---|---|---|
Topical ocular |
Oral |
Topical ocular |
Oral |
|||||
Saline | Prop | Saline | Prop | Saline | Prop | Saline | Prop | |
Corneal thickness, μm | 166.4 ± 9.9 | 190.5 ± 8.1 | 154.3 ± 4.3 | 137.5 ± 4.0 | 144.7 ± 13.5 | 151.1 ± 28.5 | 138.0 ± 13.5 | 130.6 ± 5.9 |
n = 10 | n = 10** | n = 10## | n = 10**## | n = 16§§ | n = 10§§ | n = 16§§ | n = 10#§§ | |
No. corneal epithelial cells | 244.5 ± 39.1 | 281.6 ± 35.8 | 256.0 ± 11.3 | 271.4 ± 11.9 | 387.1 ± 29.5 | 301.9 ± 9.3 | 445.6 ± 13.2 | 245.6 ± 13.4 |
n = 10 | n = 10* | n = 10 | n = 10** | n = 16§§ | n = 10** | n = 12##§§ | n = 10##§ | |
Tortuosity index | 0.96 ± 0.02 | 0.97 ± 0.028.1 | 0.91 ± 0.06 | 0.97 ± 0.03 | 0.94 ± 0.04 | 0.97 ± 0.009 | 0.92 ± 0.03 | 0.95 ± 0.03 |
n = 28 | n = 21 | n = 8 | n = 19 | n = 17 | n = 10 | n = 22 | n = 22 | |
Artery diameter, μm | 27.5 ± 6 | 25.7 ± 7 | 23.2 ± 5.4 | 26.6 ± 6.6 | 30.6 ± 4.9 | 29.5 ± 8.1 | 29.4 ± 4.5 | 30.9 ± 6.4 |
n = 46 | n = 27 | n = 15 | n = 24 | n = 34 | n = 25 | n = 38 | n = 36 | |
Vein diameter, μm | 37.1 ± 7.4 | 40.2 ± 7.8 | 38.8 ± 7.9 | 36.5 ± 7.5 | 36.7 ± 8.6 | 37 ± 5.6 | 41.1 ± 8.7 | 38 ± 5.8 |
n = 39 | n = 22 | n = 12 | n = 22 | n = 21 | n = 15 | n = 32 | n = 23 | |
Neovascularization | 1820.7 ± 823.5 | 1376.8 ± 258.7 | 1249.9 ± 504.5 | 1422.9 ± 348.5 | 2560.1 ± 364.2§ | 1979.6 ± 463.5**§§ | 2208.8 ± 419.8§§ | 1790.0 ± 362.6* |
Number of cells in NFL/GCL | 145.3 ± 45.7 | 179.6 ± 59.8 | 168 ± 36.9 | 208.5 ± 39 | 173 ± 109 | 172.3 ± 56.2 | 134.7 ± 52.8 | 174.5 ± 44.9 |
n = 3 | n = 3 | n = 5 | n = 6 | n = 9 | n = 9 | n = 9 | n = 9 | |
Total retinal thickness, μm | 306.7 ± 43.1 | 350.5 ± 27.4 | 341.7 ± 63.4 | 335.3 ± 63.2 | 296.8 ± 48.8 | 322.9 ± 96.7 | 297.9 ± 55 | 292. ± 42.3 |
n = 6 | n = 4 | n = 8 | n = 12 | n = 6 | n = 6 | n = 8 | n = 8 | |
NFL/GCL thickness, μm | 39.1 ± 1.5 | 52.4 ± 18.8 | 37.8 ± 7.2 | 38.4 ± 9.2 | 33 ± 10.9 | 33 ± 6.2 | 38.2 ± 4.2 | 32.8 ± 6.3 |
n = 6 | n = 4 | n = 8 | n = 12 | n = 6 | n = 6 | n = 8 | n = 8 | |
IPL thickness, μm | 47.3 ± 8.7 | 62 ± 6.7 | 68.8 ± 14.1 | 73.8 ± 18.2 | 56.6 ± 13.2 | 64.1 ± 19.4 | 69.7 ± 18 | 52 ± 7.7 |
n = 6 | n = 4 | n = 8 | n = 12 | n = 6 | n = 6 | n = 8 | n = 8 | |
INL thickness, μm | 56.5 ± 10.1 | 64.5 ± 1.5 | 66 ± 14.9 | 72.7 ± 16.3 | 53.7 ± 12.3 | 67.9 ± 25.5 | 48 ± 23 | 51.3 ± 8.7 |
n = 6 | n = 4 | n = 8 | n = 12 | n = 6 | n = 6 | n = 8 | n = 8 | |
ONL thickness, μm | 90.4 ± 19.2 | 93.5 ± 3.2 | 95.9 ± 17.5 | 100.2 ± 15.8 | 91.8 ± 13.6 | 96.5 ± 24.8 | 83.4 ± 30.9 | 82.7 ± 12.8 |
n = 6 | n = 4 | n = 8 | n = 12 | n = 6 | n = 6 | n = 8 | n = 8 |
Data are mean ± SD. One-way ANOVA with Bonferroni's post hoc test was used to compare data among the topical ocular or oral groups. Unpaired t-test was used to compare RA versus IH.
P < 0.05; **P < 0.01 saline versus propranolol; #P < 0.05; ##P < 0.01 topical ocular versus oral; §P < 0.05, §§P < 0.01 RA versus IH.